361 Capital’s Ionis Pharmaceuticals IONS Stock Holding History

361 Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,823	Closed	-$512K	–	350
2020 Q1	$512K	Sell	10,823 -43	-0.4%	-$2.4K	0.23%	230
2019 Q4	$656K	Buy	+10,866	New	+$647K	0.18%	248
2017 Q3	–	Sell	-31,366	Closed	-$1.6M	–	274
2017 Q2	$1.6M	Buy	+31,366	New	+$1.46M	0.27%	115

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

361 Capital's IONS Position: Q2 2020 in Review

361 Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2020, closing a stake of 10,823 shares — an estimated $512K sold.

361 Capital first reported a position in IONS in Q2 2017 and held it in 3 quarters. The position peaked at $1.6M in Q2 2017. 376 funds tracked by Wall St. Rank hold IONS as of Q2 2020.

361 Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
361 Capital sold 10,823 Ionis Pharmaceuticals shares in Q2 2020, an estimated $512K.
361 Capital first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 3 quarters.
361 Capital's Ionis Pharmaceuticals position peaked at $1.6M in Q2 2017.
376 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.